

**2019-2020**

**American Heart Association**

**Support from Pharmaceutical and Biotech Companies, Device Manufacturers and Health Insurance Providers**

We value the trust placed in us by our donors, supporters and the general public, and we feel the best way to continue to earn that trust is to make the association’s finances as transparent as possible. In fact, the American Heart Association has consistently met the high standards of the [Better Business Bureau’s Wise Giving Alliance \(WGA\)](#), the premier organization evaluating charitable organizations.


Most of the revenue recorded by the American Heart Association comes from sources other than corporations. These sources include contributions from individuals, foundations and estates as well as investment earnings and revenue from the sale of educational materials.

Financial support from corporations helps the association’s programs and campaigns more effectively achieve our goals of improving the cardiovascular health of all Americans and saving more lives. All corporate relationships are required to comply with the association’s corporate relations policies, and regional and national corporate relationships are approved by a committee of national volunteers and executive staff.

Total corporate support is comprised of unrestricted gifts and special event and program sponsorships, and includes support committed to the American Heart Association at the national, regional and local levels. Corporate Support represents approximately 23.8 percent of the AHA’s \$795 million total revenue.

Support that the American Heart Association receives from pharmaceutical and biotech companies, device manufacturers and health insurance providers is included within total corporate support and represents approximately 5.0 percent of the association’s total revenue. The majority of funding from these sources occurs at the national level.

The revenue figures below include the total amount of funds committed to the American Heart Association during fiscal year 2019-2020, noting that, in some cases, the funds will be received in future years. The chart provides funds committed from pharmaceutical and biotech companies, device manufacturers and health insurance providers in proportion to all sources of revenue.



Following is a schedule of corporate support provided to the American Heart Association from pharmaceutical and biotech companies, medical device manufacturers and health insurance providers during fiscal year 2019-2020. The schedule reflects cash received during fiscal year 2019-2020 and revenue committed to the American Heart Association that will be received in future years.

| 2019-2020 Corporate Support Received from Pharmaceutical and Biotech Companies, Medical Device Manufacturers and Health Insurance Providers |  |  |
|---|--|--|
| Corporation   | Total Cash Received During 2019-2020 on Prior and Current Year Commitments (1) | 2019-2020 Commitments Receivable in the Future |
| 3M  | \$ 100,000   | \$ -   |
| Abbott  | -  | 124,998  |
| Amarin  | 775,000  | -  |
| AmerisourceBergen   | 200,000  | -  |
| Amgen   | 3,275,000  | 1,950,000                                      |
| Alnylam Pharmaceuticals   | 250,000  | -  |
| Anthem  | 1,639,518  | 4,326,040                                      |
| AstraZeneca   | 6,482,500  | 105,000  |
| Bard/BD   | 200,000  | 60,000   |
| Bayer Healthcare  | 1,808,333  | 833,333  |
| Biogen  | 22,500   | -  |
| Blue Cross Blue Shield of NC  | 500,000  | -  |
| Blue Shield of California   | 250,000  | -  |
| BMS/Pfizer  | 635,819  | -  |
| BI/Lilly  | 2,002,269  | 3,000,000                                      |
| Boehringer Ingelheim Pharmaceuticals  | 1,822,450  | -  |
| Cerenovus   | 25,000   | -  |
| Chiesi  | 15,000   | -  |
| CSL Behring   | 30,000   | -  |
| Cytokinetics  | 80,000   | -  |
| Data Sciences International   | 1,000  | -  |
| Delta Dental  | 31,250   | 483,750  |
| Denka Seiken USA  | 20,000   | -  |
| Edwards Lifesciences LLC  | 3,800,000  | 6,500,000                                      |
| Esperion Therapeutics, Inc.   | 180,000  | -  |
| FirstKind Ltd   | 24,965   | -  |
| Florida Blue  | -  | 300,000  |
| Genentech   | 410,500  | -  |
| Gore Medical  | 30,000   | -  |
| Humana  | 25,000   | -  |
| Independence Blue Cross   | 125,000  | -  |
| Jabil   | 75,000   | -  |
| Janssen   | 457,500  | -  |
| Janssen Biotech   | 283,335  | 120,000  |
| Johnson & Johnson   | 383,137  | -  |
| Kaiser Permanente   | 525,000  | -  |
| Laerdal Medical Corporation   | 600,000  | 1,350,000                                      |
| Livongo Health  | 25,000   | -  |
| Medtronic/Covidien/EV3  | 1,257,150  | 912,500  |
| Merck   | 105,000  | -  |
| MyoKardia   | 940,000  | 2,390,000                                      |
| Nephron Pharmaceuticals   | 75,000   | -  |
| Novartis Pharmaceuticals  | 3,082,187  | -  |
| NovoNordisk   | 1,635,000  | -  |
| Parker Hannifin   | 62,500   | -  |
| Pfizer  | 388,325  | -  |
| Philips Healthcare  | 125,000  | -  |
| Portola Pharmaceuticals, Inc.   | 1,467,724  | 2,600,000                                      |
| Quest Diagnostics   | 17,500   | -  |
| Reckitt Benckiser   | 125,000  | -  |
| Regeneron   | 50,000   | -  |
| Sanofi  | 1,775,000  | -  |
| Schiller Americas, Inc.   | 37,500   | 512,500  |
| Siemens USA   | 200,000  | -  |
| Stryker Neurovascular   | 15,000   | -  |
| Syntheon  | 20,000   | -  |
| The Medicines Company   | 360,000  | -  |
| Transamerica  | 500,000  | -  |
| UnitedHealthcare  | 75,000   | -  |
| Verily (Google Life Science)  | 4,717,409  | -  |
| Verve Therapeutics  | 5,000  | -  |
| Western Health Advantage  | 115,000  | -  |
| <b>Totals</b>   | <b>\$ 44,260,371</b>   | <b>\$ 25,568,121</b>                           |

NOTE: (1) Reflects all cash received from corporate contributions to National Center and ten highest corporate contributions to each Region. Revenue related to the cash receipts was recorded within AHA's financial statements over the periods from fiscal year 2014-2015 through fiscal year 2019-2020.